​

Marker Therapeutics (MRKR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

MRKR Stock Rating

Marker Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 1 Strong Buy (20.00%), 2 Buy (40.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 2 1 Strong Sell Sell Hold Buy Strong Buy

MRKR Price Target Upside V Benchmarks

TypeNameUpside
StockMarker Therapeutics-
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.15$1.15$1.15
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25-3---3
Mar, 25-2---2
Feb, 25-1---1
Jan, 25-1---1
Dec, 24-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 05, 2025Canaccord GenuityBuyinitialise
Mar 21, 2021Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-2M $-1M $-900K $-600K $-300K $0 Dec 20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-6.06$-3.58$-1.93$-1.19M---
Avg Forecast$-5.90$-3.60$-3.40$-1.05$-2.19$-2.59$-1.13
High Forecast$-5.90$-3.60$-3.40$-1.05$-2.19$-2.59$-1.13
Low Forecast$-5.90$-3.60$-3.40$-1.05$-2.19$-2.59$-1.13
Surprise %2.71%-0.56%-43.24%113809080.95%---

Revenue Forecast

$0 $1T $3T $4T $6T $7T Dec 20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$466.79K$9.00M$3.31M$6.59T---
Avg Forecast$483.50K$9.00M$3.31M$5.34M$4.00M$2.00M$37.97M
High Forecast$483.50K$9.00M$3.31M$5.34M$4.00M$2.00M$37.97M
Low Forecast$483.50K$9.00M$3.31M$5.34M$4.00M$2.00M$37.97M
Surprise %-3.46%0.05%-123451482.69%---

Net Income Forecast

$-15T $-12T $-9T $-6T $-3T $0 Dec 20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-28.53M$-29.92M$-14.05M$-10.73T---
Avg Forecast$-51.98M$-31.71M$-29.95M$-9.25M$-19.29M$-22.82M$-9.95M
High Forecast$-51.98M$-31.71M$-29.95M$-9.25M$-19.29M$-22.82M$-9.95M
Low Forecast$-51.98M$-31.71M$-29.95M$-9.25M$-19.29M$-22.82M$-9.95M
Surprise %-45.12%-5.67%-53.11%116015972.47%---

MRKR Forecast FAQ

Is Marker Therapeutics stock a buy?

Marker Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 2 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Marker Therapeutics is a favorable investment for most analysts.

What is Marker Therapeutics's price target?

Marker Therapeutics's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.15.

How does Marker Therapeutics stock forecast compare to its benchmarks?

Marker Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Marker Therapeutics over the past three months?

  • April 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Marker Therapeutics’s EPS forecast?

Marker Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.19, marking a -100.00% decrease from the reported $-1.195M in 2024. Estimates for the following years are $-2.59 in 2026, and $-1.13 in 2027.

What is Marker Therapeutics’s revenue forecast?

Marker Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4M, reflecting a -100.00% decrease from the reported $6.59T in 2024. The forecast for 2026 is $2M, and $37.97M for 2027.

What is Marker Therapeutics’s net income forecast?

Marker Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-19.293M, representing a -100.00% decrease from the reported $-10.731T in 2024. Projections indicate $-22.816M in 2026, and $-9.955M in 2027.